Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer
Sponsor: Genentech, Inc.
A PHASE2 clinical study on Carcinoma, Non-small-cell Lung, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Konstantin Dragnev
- Ligand Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Lebanon, United States
- • New York, United States